

Form 605Corporations Act 2001
Section 671B**Notice of ceasing to be a substantial holder**To: Company Name/Scheme Neuren Pharmaceuticals limitedACN/ARSN ARBN 111 496 130**1. Details of substantial holder(1)**Name BioAsia Investments IV, LLC

ACN/ARSN (if applicable) _____

The holder ceased to be a
substantial holder on11/25/08

The previous notice was given to the company on

2/11/10

The previous notice was dated

2/11/10**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change(5)	Class (6) and number of securities affected	Person's votes affected
10/2/08	Biotechnology Development Fund IV, LP	Sold	USD 56,427.26	1,405,228	0.55%
11/25/08	Biotechnology Development Fund IV Affiliates, LP	"	USD 860.75	25,681	0.01%
11/25/08	BioAsia Crossover Fund	"	USD 13,154.65	338,700	0.13%

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Biotechnology Development Fund IV, LP	c/o BioAsia Investment IV, LLC
Biotechnology Development Fund IV Affiliates, LP	575 High St. #201, Palo Alto, CA 94301
BioAsia Crossover Fund, LP	

Signature


print name

Frank Kung

capacity

Managing Member

sign here



date

Feb '11 / 2010